Clinical trials: Carcinoma, Transitional Cell
Urothelial Carcinoma
Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation
This is a prospective, open, single center clinical study of vidicizumab combined with local radiotherapy as bladder conserving therapy in patients with muscle invasive bladder urothelium cancer with HER-2 expression (IHC 2+or…
- Trial name
- NCT05912205
- Testing
- Disitamab Vedotin, radiotherapy
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Transitional Cell Carcinoma of Bladder
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG (number of participants with AEs, discontinuations due to AEs) Recurrence after treatment with BC-819/PEI and BCG Approximately 38…
- Trial name
- NCT01878188
- Testing
- BC-819/PEI, BCG Vaccine
- Where
- 7 sites in Israel
- Volunteers
- 38 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Upper Tract Urothelial Carcinoma
Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma
The aim of this study is to explore feasibility of Upper Tract Urothelial Carcinoma (UTUC) treatments based in real world data in various European countries.
- Trial name
- URANUS (NCT02969083)
- Testing
- RNU, Gemcitabine/Cisplatin, M-VAC Protocol
- Where
- 29 sites in Netherlands, Norway and 1 more
- Volunteers
- 200 people
- Sponsor
- The European Uro-Oncology Group
Urothelial Carcinoma (UC), HER2
Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics
This study aims to build upon previous research by using artificial intelligence methods to fuse multimodal data from imaging and pathology to construct a predictive model for HER2 expression in urothelial carcinoma.
- Conditions
- Urothelial Carcinoma (UC), HER2, Diagnostic
- Trial name
- NCT07454941
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Bladder Cancer
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Green tea extract (Polyphenon® E) contains certain ingredients that may slow the growth of tumor cells and prevent the…
- Trial name
- NCT00088946
- Testing
- Polyphenon E, erlotinib hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Urothelial Carcinoma
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
In cohort 1 of this study, we used an attenuated schedule of neoadjuvant ipilimumab and nivolumab. In the multicenter extension (cohort 2), 30 patients were randomized between two neoadjuvant treatment schemes, both based upon an…
- Trial name
- NABUCCO (NCT03387761)
- Testing
- Ipilimumab, Nivolumab
- Where
- 3 sites in Netherlands
- Volunteers
- 54 people
- Sponsor
- The Netherlands Cancer Institute
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
Background: In European Association of Urology (EAU) Guidelines, the vast majority of non-muscle-invasive bladder cancers (NMIBCs) undergo a primary transurethral resection of the bladder tumor (TURBT) followed by a repeat TURBT…
- Conditions
- Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- CUT-less (NCT05962541)
- Testing
- PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM)
- Where
- Italy
- Volunteers
- 327 people
- Sponsor
- University of Roma La Sapienza
Urothelial Carcinoma, Triple Negative Breast Cancer
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4…
- Conditions
- Urothelial Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05234606
- Testing
- SBT6290, pembrolizumab
- Sponsor
- Silverback Therapeutics
Urinary Tract Cancer, Urothelial Carcinoma
CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma
Rationale: Initial evaluation usually consists of cross sectional imaging of the urinary tract. When a suspect lesion is seen, an ureterorenoscopy is planned to visualize the lesion and to collect tissue for histopathology.
- Conditions
- Urinary Tract Cancer, Urothelial Carcinoma, Ureter Cancer
- Trial name
- NCT03013920
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Solid Tumors, Urothelial Carcinoma
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid…
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03076372
- Testing
- MM-310
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merrimack Pharmaceuticals
Bladder Cancer
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Gemcitabine and Cisplatin are standard chemotherapy drugs used to treat advanced urothelial cancer. There is no standard chemotherapy for patients who cannot receive Cisplatin.
- Trial name
- NCT01622660
- Testing
- Gemcitabine, Pazopanib
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Carcinoma
Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy
This is a 2-arm, prospective, randomized (2:1 ratio), open-label, multi-centre, phase II study conducted in patients affected by unresectable, locally advanced or metastatic urothelial cancer receiving niraparib plus best…
- Trial name
- NCT03945084
- Testing
- Niraparib, Best supportive care
- Where
- 20 sites in Italy
- Volunteers
- 58 people
- Sponsor
- University of Turin, Italy
Urothelial Carcinoma, Urinary Bladder Cancer
Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
To facilitate the follow-up of urothelial tumors and also make them more tolerable and less invasive for patients, there is a minimally invasive and easy to perform examination which is urinary cytology on 3 samples.
- Conditions
- Urothelial Carcinoma, Urinary Bladder Cancer, Urinary Tract Cancer
- Trial name
- NCT04718948
- Testing
- Urinary Multimodal Fiber Optic Spectroscopy, Urine Cytology, Surgery
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Florence
HNSCC, NSCLC
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic stages.
- Conditions
- HNSCC, NSCLC, Esophageal Cancer, Urothelial Carcinoma
- Trial name
- ST-ICI02 (NCT04892849)
- Testing
- Conventional Therapy acc. to prevailing clincal approved schemes
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Upper Tract Urinary Carcinoma, Muscle-invasive Bladder Cancer
Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma
Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies showed this neoadjuvant…
- Trial name
- NCT04099589
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer, Breast Cancer
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma
- Trial name
- NCT04440943
- Testing
- CDX-527
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celldex Therapeutics
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02496208
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 8 sites in United States
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
This study plans to learn more about the combination of AMG 386 and docetaxel for the treatment of advanced urothelial cancer. Subjects are being asked to be in this research study because they have advanced urothelial cancer…
- Trial name
- NCT01907308
- Testing
- AMG 386, Docetaxel
- Sponsor
- University of Colorado, Denver
Transitional Cell Carcinoma
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body.
- Trial name
- NCT02581982
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.